







Editing file



Bleeding disorders

Objectives:

- ★ Overview of Hemostasis.
- ★ Congenital Bleeding Disorders.
- ★ Acquired Bleeding Disorders.
- ★ Platelet Disorders (Number & Function).
- ★ Approach to the bleeding Pt.
- ★ Management of Bleeding Pt.

Color index:

Original text Females slides Males slides Doctor's notes Textbook Important Golden notes Extra

Overview

Bleeding disorder


Bleeding disorders are a group of disorders that share the **inability to form a proper blood clot.** They are characterized by **extended bleeding after injury, surgery, trauma or menstruation.**

Hemostasis

- The process through which bleeding is controlled at a site of damaged or disrupted endothelium.
- A dynamic interplay between:
- 1. Cellular Components: (PLTs & Endothelium)
- 2. Plasma Proteins Components: 3 protein systems :
 - Blood Coagulation (Clot Formation)
 - Fibrinolysis (Clot Lysing)
 - Anticoagulant (Regulating)¹

Recall the normal hemostatic process which comprises 4 main steps :

- Injury of blood vessels and rapid vasoconstriction.
- Temporary platelet plug.
- Blood coagulation by activation of the clotting cascade.
- Fibrinolytic system activation (clot dissolve by plasmin).



1- It is a natural process in our body to stop further thrombosis events.

2- To assess the hemostatic system if it works probably .


Platelets


Platelet:


- Produced in the Bone Marrow by fragmentation of the cytoplasm of megakaryocytes.
- Each megakaryocytes rise Plt from **1000 to 5000**.
- Time interval from differentiation of the human stem cell to the production of Plts (~10 days) (MCQ)
- Thrombopoietin is the major regulator of Plt production via c-MPL receptor (produced by the liver & kidney).
- Normal PLT counts (150 400 x 10⁹). (Usually we can do surgeries if plt count was <50k, except CNS surgeries, it has to be >100k.)
- PLT Life Span (7 10 days). MCQ

Platelet ultrastructure :

★ Extremely small & discoid (3 x 0.5 µm in diameter).







PLTs functions :

Adhesion

Adhesion between the **PLT and the vessel wall by VWF through <u>GP Ib</u>/IX/V** (synthesized in endothelial cells & megakaryocytes / stored in storage granules of endothelial cells & α granules of Plt / Rise with stress, exercise, adrenaline, infusion of DDAVP).

Deficiencies in any of them produce a different disease

2

3

Aggregation

By cross linking of **PLT to PLT by VWF & Fibrinogen through <u>GP IIb/IIIa receptors</u> (on the surface of the PLT).**

Release Reaction & Amplification

- (aggregation formation & stabilization)
- Release of α granules contents, & ADP from dense granules.
- □ Formation of **Thromboxane A2** (through COX enzymes. Aspirin works by inhibiting COX enzyme thus decreasing TXA2 production) by various agonists induces intracellular signaling & thrombin formation

PLTs Inhibitors: The goal is just to stop the bleeding. We don't want extra aggregation.

Prostacyclin (PGI2);

- Synthesized by vascular endothelial cells. Think of it as a TXA2 antagonist.
- **Potent inhibitor of PLT aggregation** & causes mild vasodilation by rising cAMP.
- Prevents Plt deposition on normal vascular endothelium

- Nitric Oxide (NO);
- Released from endothelial cells, macrophages, & platelets.
- Inhibits Plt activation & **promotes** vasodilation.

They provide the energy for the platelets to aggregate together in the fibrin.
 essential co-factor in coagulation cascade.

Hemostasis

Hemostasis dependent upon :

- Vessel Wall Integrity.
- Adequate Levels of Clotting Factors.
- Proper Function of Fibrinolytic Pathway.
- **Proper Functioning Platelets.**

Adequate Numbers of Platelets.

Hemostatic phases : (MCO)



- 1. Endothelium Injury
 - 2. Platelet plug
 - 3. Von Willebrand Factor

Secondary Hemostasis

Platelet phase:

- 1. Clotting Factors
- 2. Soluble Protein Fibrinogen converted to insoluble Fibrin.



Vascular phase :

release of locally active vasoactive agents (Endothelin, Thromboxane A2, Fibrinopeptides) lead to vasoconstriction at the site of injury that leads to reduced blood flow.



Plt Adhesion & Aggregation (via VWF, ADP, TXA2) will result in formation of **PLT Plug**.




Plasma coagulation phase:


Propagation of the clotting process by the coagulation cascade lead to formation of Fibrin Clot.



Fibrinolysis change :

Termination of clotting by antithrombotic control mechanisms & removal of the clot.





Primary VS secondary hemostasis

Primary hemostasis refers to platelet aggregation and platelet plug formation. Secondary hemostasis refers to the deposition of insoluble fibrin, which is generated by the proteolytic coagulation cascade. This insoluble fibrin forms a mesh that is incorporated into and around the platelet plug.

- Defect in $1ry \rightarrow$ Mucosal bleeding; normal PT/PTT
- Defect in 2ndry \rightarrow Deep tissue bleeding; abnormal PT/PTT, depending of the pathway affected:
 - Intrinsic pathway \rightarrow prolonged PTT
 - Extrinsic pathway \rightarrow prolonged PT
 - If both are prolonged think of DIC



Hemostasis

Clotting factors: produced by the liver

Clotting Factors in Blood and Their Synonyms

Clotting Factor

Fibrinogen Prothrombin Tissue factor Calcium Factor V


Factor VII

Factor VIII Congenital deficiency → hemophilia A Factor IX Congenital deficiency → hemophilia B Factor X Factor XI

Factor XII Factor XIII Prekallikrein High-molecular-weight kininogen Platelets Synonyms Factor I Factor II Factor III; tissue thromboplastin Factor IV Proaccelerin; labile factor; Ac-globulin (Ac-G) Serum prothrombin conversion accelerator (SPCA); proconvertin; stable factor Antihemophilic factor (AHF); antihemophilic globulin (AHG); antihemophilic factor A Plasma thromboplastin component (PTC); Christmas factor; antihemophilic factor B Stuart factor; Stuart-Prower factor Plasma thromboplastin antecedent (PTA); antihemophilic factor C Hageman factor Fibrin-stabilizing factor Fletcher factor Fitzgerald factor; HMWK (high-molecular-weight) kininogen


for easy memorization 01.Freshers- Fibrinogen
02.Party- Prothrombin
03.Today- Thromboplastin
04.Come on- Calcium
05.Let's- Labile factor
05.Let's- Labile factor
07.Sing- Stable factor
08.And- Anti Haemophilic factor
09.Call the- Christmas factor
10.Seniors- Stuart prower factor
11.Please- PTA
12.Have- Hageman factor
13.Fun- Fibrin stabilizing factor

Coagulation cascade:




The intrinsic pathway gets activated when the blood vessel gets injured. It starts by the activation of factor 12 when it comes in contact with the Subendothelial collagen of the injured vessel.
To prevent further coagulation: 1) platelet inhibitors 2) protein C & S: they deactivate factor 5 & 8
What are the VitK dependent factors? II, VII, IX, X, proteins C & S

Fibrinolysis :







Dysfibrinogenaemia:

is a coagulation (clotting) disorder characterized by having an abnormal form of fibrinogen. Having abnormal fibrinogen results in defective clot formation and can cause an increased or decreased ability to clot.

CONGENITAL BLEEDING DISORDERS

Hemophilia :

- An inherited bleeding disorder caused by deficiency of coagulation. (The most common inherited disorder)
 - It's characterized based on the residual or baseline factor activity level (also referred to as "factor level"); expressed as a % of normal or in IU/mL.
 - Factor levels typically correlate with the degree of bleeding Symptoms. (Important)

Hemophilia **Congenital:** Acquired : genetic mutation in F8 & F9 located on the long arm • Development of **autoantibodies** most of X chromosome. commonly directed against **FVIII** – ass. with Observed commonly in males due to their pregnancy, malignancy, advanced age. hemizygous state. (anything that triggers the immune system to Rarely in females due to (Heterozygous females as produce autoantibodies) result from nonrandom X chromosome inactivation, skewed Lyonization¹, or the presence of other genetic abnormalities (Turner Syndrome or X autosomal translocations). Types Hemophilia C : Inherited deficiency of Hemophilia A: Inherited ٠ Hemophilia B : factor XI (11); also called Rosenthal deficiency of factor VIII (8); an Inherited deficiency of Syndrome; an autosomal recessive X-linked recessive disorder factor IX (9); also called disorder. Rarely, heterozygotes may (male diseased and female Christmas Disease: an have bleeding (ie, autosomal dominant carrier). It is protected from X-linked recessive transmission, due to heterodimer proteolysis in the circulation binding). especially common in disorder. Ashkenazi Jews (ie, Jews from Eastern by binding to vWF. Europe). hematomas, hemarthrosis, bruising, bleeding (mucosal, GI, GU, joint) Clinically deep bleeding. (traumatic bleeding) Diagnosis Increased aPTT, Factor level will be low, Mixing study (corrected in case of congenital only, not corrected in acquired), Normal VWF & PT. Replacement of the deficient coagulation Factor (recombinant or plasma derived) + Adjunctive therapy (Desmopressin (DDAVP levels of vwf will increase with this drug), Antifibrinolytic agents (Tranexamic Acid, Aminocaproic Acid), rFVIIa (with inhibitors).

1-It means the female has only one X and the other one is inactive .

CONGENITAL BLEEDING DISORDERS

Baseline factor activity level² (MCO) Severe Hemophilia : defined as <1 % factor activity (<0.01 IU/mL).³ **Moderate Hemophilia** : defined as a factor activity level ≥ 1 % of normal and < 5 % of normal (≥ 0.01 - <0.05 IU/mL).4 **Mild Hemophilia :** defined as a factor activity level $\geq 5\%$ of normal and <40% of normal (≥ 0.05 -* <0.40 IU/mL).5 Von Willebrand Disease : The most common bleeding disorder. ✦ Inherited VWD is classified into Three types. Defect of Von Willebrand Factor: • Quantitative (type 1 & 3) • Qualitative (type 2) Autosomal dominant. (MCO) The Normal function of VWF: Mediate platelet adhesion. • Stabilize factor VIII in circulation.¹ Localize factor VIII to site of vessel injury. **Congenital :** autosomal dominant (most types), recessive (rarely).

Acquired : rare, caused by autoantibodies against vWF & immune complex formation, vWF binding to cancer cells, Congenital Heart Disease, Aortic Stenosis, Angiodysplasia. Rx (of the underlying disorder)

Classification of von	Willebrand disease	*	Ristocetin-Induced platelet aggregation; a way to test PLT function		
Туре	Inheritance	VWF activity	RIPA	Multimer pattern	★ VWF func : 1- form an adhesive bridge
Type 1 (partial quantitative deficiency)	Autosomal dominant	Decreased	Decreased	Uniform decrease; all multimers present	between platelets and injured
Type 2 (qualitative varian	t)	vascular epithelium.			
Type 2A	Autosomal dominant or recessive	Decreased	Decreased	Decreased large multimers	2- carrier for factor VIII.
Type 2B	Autosomal dominant	Decreased	Increased	Decreased large multimers	3- form a bridge between
Type 2M	Autosomal dominant or recessive	Decreased	Decreased	Uniform decrease; all multimers present	adjacent platelets allowing them to bind together and
Type 2N	Autosomal recessive	Normal	Normal	Normal	effectively form a platelet plug
Type 3 (severe)	Autosomal recessive	Markedly decreased or absent	Markedly decreased or absent	Undetectable; usually cannot visualize	at sites of endothelial injury .

&z

group F dr focused on the highlighted while males dr said you don't need to know the details

🖈 Diagnosis


- normal aPTT in (Type 1 & 2).
- prolonged aPTT in (Type 2N, 2B, & 3)
- vWF:Ag.
- vWF:RCo.
- vWF multimers (to differentiate subtypes)
- FVIII assay (low in 2N & 3).
- Plt count (low in 2M).

- **Treatment**
- Replacement of exogenous vWF concentrate.
- **Desmopressin** (DDAVP intranasal) Antifibrinolytic agents (Tranexamic Acid Aminocaproic Acid).
- Conjugated Estrogens & oral contraceptive Agents (for menorrhagia).

1- factor VIII it is imp for the intrinsic pathway + adhesion to vascular injury to allow the PLT to underline the clotting factor . 2- By knowing the Baseline factor activity level we can manage the haemophilic patient according to these definitions . management:


3- They need **regular transfusion** /replacement of the factor to prevent any serious bleeding.

4-they don't suffer from frequent bleeding so they can have factor **replacement at time of bleeding**. 5- Minimal need for factor replacement.



CONGENITAL BLEEDING DISORDERS

Platelet aggregometry:



- Function of PLT depend on the secretion of certain substrates from the granules . Abnormality in the granules → "platelet function difficulty" or what is called "thrombasthenia" in which they will be unable to aggregate normally and give very weak wave (Red) while the blue waves are normal.
- To confirm, test for platelet ristocetin activity. In case of VWF disease all will be normal except ristocetin.

Comparison between haemophilia and VWD : 📩

	Hemophilia A	Factor IX deficiency	Von Willebrand
inheritance	Sex linked	Sex linked	Dominant (incomplete)
Main sites of hemorrhage	Muscle,joints,post- trauma or postoperative	Muscle,joints,post- trauma or postoperative	Mucous membranes, skin cuts, post-trauma or postoperative
Platelet count	Normal	Normal	Normal
Bleeding time	Normal	Normal	Prolonged
Prothrombin time	Normal	Normal	Normal
Partial thromboplastin time	Prolonged	Prolonged	Prolonged or Normal
Factor VIII	Low	Normal	May be moderately reduced
Factor IX	Normal	Low	Normal
vWF	Normal	Normal	Low
Ristocetin-induced platelet aggregation	Normal	Normal	Impaired

1- It stimulate endogenous production of VWF .

Plt Disorders (Quantitative) :

Just know the name

Causes of Thrombocytopenia:

Falsely low pla	stelet counts (ie, pseudothrombocytopenia)
In vitro platelet	clumping caused by EQTA-dependent agglutinins
In vitro platelet	clumping caused by an insufficiently anticoagulated specimen
In vitro platelet	clumptin caused by glycoprotein IIb/IIIa inhbitors (eg, abciximab) (NOTE: these can also cause true thrombocytopenia)
Giant platelets c	ounted by automated counter as white blood cells rather than platelets
Common cause	es of thrombocytopenia
Drug-induced t	hrombocytopenia
Heparin (NOTE:	special case, also can cause thrombosis)
Quinine (as in o	ver-the-counter preparations for leg cramps; also in beverages)
Sulfonamides (e	g, trimethoprim-sulfamethoxazole [Bactrim; Septra])
Acetaminophen	(Tylenol, Panadol)
Cimetidine (Tag	amet)
Ibuprofen (Advil	, Motrin)
Naproxen (Aleve	, Midol)
Ampicillin (Omni	pen, Apo-Ampi)
Piperacillin (Pipr	acil, Zosyn)
Vancomycin (Va	ncocin)
Glycoprotein IIb	/IIIa inhibitors (abciximab [ReoPro], tirofiban [Aggrastat], eptifibatide [Integrilin])
Food and bever	ages
Quinine-containi	ng beverages (tonic water, Schweppes bitter lemon)
Infections	
HIV	

Pseudothrombocytopenia or spurious thrombocytopenia

is an in-vitro sampling problem which may mislead the diagnosis towards the more critical condition of thrombocytopenia. The phenomenon occurs when the anticoagulant used while testing the blood sample causes clumping of platelets which mimics a low platelet count.

Other causes of thrombocytopenia
Nyelodysplasia
Suspected in older patients, in whom a bone marrow biopsy may be appropriate
Cancer with disseminated intravascular coagulation
Cancer with bone marrow infiltration or suppression (eg, lymphoma, leukemia, some solid tumors)
Paroxysmal nocturnal hemoglobinuria (PNH)
Thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS)
TTP is a syndrome that can include thrombocytopenia, microangiopathic hemolytic anemia, fever, renal failure, and neurologic symptoms. However, patients with TTP commonly present with thrombocytopenia and anemia alone.
HUS is typically a disorder of young children following infection with a Shiga-toxin producing E. coli.
Antiphospholipid syndrome (APS)
Aplastic anemia
Congenital thrombocytopenias
An important consideration, especially in young patients who do not respond to treatment. Some specific syndromes are listed. However, many patients appear to have autosomal dominant thrombocytopenia with no other clinical features.
Von Willebrand disease type 2B
Wiskott-Aldrich syndrome
Aport syndrome
May-Hegglin anomaly
Fanconi syndrome
Bernard-Soulier syndrome
Thrombocytopenia absent radius syndrome

Infections
HIV
Hepatitis C
Epstein-Barr virus (EBV; can be associated with infectious mononucleosis)
H. pylori (suspected in patients with symptoms of dyspepsia or peptic ulcer disease)
Sepsis with disseminated intravascular coagulation (DIC)
Intracellular parasites (eg, malaria, babesia)
Hypersplenism due to chronic liver disease
Alcohol
Nutrient deficiencies (eg, vitamin B12, folate, copper)
Rheumatologic/autoimmune disorders (eg, systemic lupus erythematosis, rheumatoid arthritis)
Pregnancy
Gestational thrombocytopenia
Preeclampsia
HELLP syndrome (hemolysis, elevated liver function tests, low platelets)

Platelets Disorders


Approach to Thrombocytopenia

I have a patient's CBC that shows thrombocytopenia.

-First ask to examine the peripheral blood smear under the microscope, if there's platelet plugging, then there's pseudothrombocytopenia, & ask for the CBC to be repeated on citrate.

-If it is true thrombocytopenia:

- Look in the peripheral blood morphology, if there is:
 - Fragmented RBCs, then this is consumption coagulopathy, which means there is a problem in the blood leading to more coagulation and platelet consumption. This is present in TTP, HUS, & DIC. It is diagnosed by elevated LDH & bilirubin, low haptoglobin, prolonged PT & aPTT.
 - If you take a BM biopsy and find blast cells, then it means that there is a problem in the factory (bone marrow; possibly leukemia) Refer to Hematologist.
 - \circ Clumped or agglutinated RBCs \rightarrow consider Evans syndrome (autoimmune hemolytic anemia with autoimmune thrombocytopenia; characterized by reticulocytosis & +ve Coomb's test, increased LDH & bilirubin)
 - \circ Elevated levels of lymphocytes/neutrophils \rightarrow consider an infection
 - \circ Isolated thrombocytopenia \rightarrow consider ITP (idiopathic thrombocytopenia) or viral infection




Immune Thrombocytopenic Purpura (ITP): 🔭

1

Primary: isolated thrombocytopenia due to immune Plt destruction & reduce production (auto AB to megakaryocytes)


Secondary: Associated with (disease/drug exposure) so look for any Viral (HIV, HCV, HBV, EBV, CMV, Parvovirus), SLE, APLS, H. Pylori Infection, If you didn't find any of the previous causes look for: Chronic Lymphocytic Leukemia (CLL), Hodgkin Lymphoma, AIHA.



- PBS (Large Plts).
- Anti-Plt AB (not useful).

- Rarely indicated if PLT > 50.000 unless bleeding, trauma/surgery, anticoag, comorbidities.
 - Treatment options:
 - Splenectomy.
 - **TPO** agonists
 - (Romiplostim,
 - Eltrombopag).

Platelets Disorders



fibrinogen this indicate he has severe infection. so we can see it as high or low in DIC.

Platelets Disorders

Plt Disorders (Qualitative):

Bernard-Soulier Syndrome \rightarrow Genetic GPIb deficiency Glanzmann thrombasthenia \rightarrow Genetic GPIIb/IIIa deficiency

- INHERITED DISORDERS OF PLT FUNCTION: Know only the names (not imp)
 - Giant platelet disorders includes Plt GP abnormalities (eg, Bernard-Soulier Syndrome, Deficiency of Platelet Alpha granules (eg, Gray Platelet Syndrome), Deficiency May-Hegglin Anomaly (which also involves the presence of abnormal neutrophil inclusions (ie, Döhle-like bodies)), & some kindreds with type 2B vWD (Montreal Plt Syndrome).
 - 2. **Storage Pool Disorders** such as Hermansky Pudlak Syndrome (HPS)
 - 3. Wiskott-Aldrich syndrome .

4. Glanzmann thrombasthenia

(aggregate in response to ristocetin).

- 5. Platelet release disorders.
- 6. Glycoprotein VI defects
- 7. Sticky platelet syndrome.
- 8. Congenital Deficiency of the ADP receptor P2Y 12.
- 9. Scott syndrome.

Approach to Pt with Potential Bleeding :

Two important points:

- 1. Detailed Pt & Family Medical History (Crucial & Vital regardless of the prior Lab testing)
- 2. Laboratory Testing.

1. Detailed Pt & Family Medical History

establish likelihood of a bleeding disorder guide laboratory Testing.

- Early in the newborn period (problem during circumcision, or bleeding in females)
- After hemostatic Challenges (Delivery, injury, trauma, surgery, invasive dental procedure, menstruation).
- Frequency & pattern .
- Duration :

o Symptoms onset (congenital vs. acquired) . o time required for cessation.

Sites of bleeding (specific or multiple) : (Very important)

Primary Hemostasis Defects (PLT or vW Factor)

Defects (Clotting Factors

Mucocutaneous Bleeding :

- Easy bruising
- Epistaxis
- Menorrhagia


Deep Tissue Blee

- Joint (Hemarthrosis)
- Muscles
- CNS (intracerebral hemorrhage)
- Current use of medications or herbal supplements .
- Use of Bleeding Assessment Tools (differentiate bleeding phenotypes, require validation by prospective studies)

Drugs Used for Clotting Disorders

14

you should know them to rule them out from the history.




Approach to Pt with Potential Bleeding

2. Laboratory Testing

Screening Tests :

- 1) CBC (Platelet count) .
- 2) Prothrombin Time (PT): measures F VII, X, V, II, I (N Time 10-14 secs).
- 3) International Normalized Ratio (INR) : the ratio of a pt's PT to a normal (control) sample, raised to the power of the ISI value for the control sample used.
- 4) Activated Partial Thromboplastin Time (aPTT or PTT) : measures F XII, XI, IX, VIII, X, V, II, I (N Time 30 40 secs) .
- 5) Thrombin (Clotting) Time (TT) : sensitive to deficiency of Fibrinogen or inhibition of thrombin (N Time 14 16 secs).
- 6) Bleeding Time : (3-8 secs) (not sensitive not specific).
- Screening tests (not sensitive to all abnormalities associated with a bleeding disorder.

Causes of prolonged coagulation profile : 🖈 SUM



Test result		Causes of test result pattern			
РТ	aPTT				
Prolonged	Normal	Inherited			
		Factor VII deficiency			
		Acquired			
		Mild vitamin K deficiency			
		Liver disease			
		Warfarin administration			
		Acquired inhibitor of factor VII			
		Lupus anticoagulant (more commonly causes isolated prolonged aPTT; may be associated with thrombosis rather than bleeding)			

Test result		Causes of test result pattern				
PT	aPTT	Causes of test result pattern				
Normal	Prolonged	Inherited				
		Deficiency of factors VIII, IX, or XI				
		Deficiency of factor XII, prekallikrein, or HMW kininogen (not associated with a bleeding diathesis)				
		von Willebrand disease (variable)				
		Acquired				
Heparin administration		Heparin administration				
		Direct thrombin inhibitor administration (eg, argatroban, dabigatran)				
		Inhibitor of factors VIII, IX, XI, or XII				
		Acquired von Willebrand disease				
		Lupus anticoagulant (may be associated with thrombosis rather than bleeding)				

Test result		Causes of test result pattern	
PT	aPTT		
Prolonged	Prolonged	Inherited	
		Deficiency of prothrombin, fibrinogen, or factors V or X	
		Combined factor deficiencies	
		Acquired	
		Liver disease	
		Disseminated intravascular coagulation	
		Supratherapeutic doses of anticoagulants	
		Severe vitamin K deficiency	
		Combined heparin and warfarin administration	
		Direct factor Xa inhibitor administration (eg, rivaroxaban, apixaban, edoxaban)	
		Fondaparinux administration (slight prolongation)	
		Inhibitor of prothrombin, fibrinogen, or factors V or X	
		Primary amyloidosis-associated factor X deficiency	
		Anticoagulant rodenticide poisoning	

Approach to Pt with Potential Bleeding

Specialized Tests :

Mixing Study (one to one mix of Pt's plasma & known normal standard plasma, only if PT of aPTT prolonged) used in case of antibody produced against the clotting factor (Acquired hemophilia).

- Corrected \rightarrow clotting factor deficiency (risk of bleed).
- Not corrected → inhibitors (directed against specific factor or global inhibitors " Lupus Inhibitor, risk of thrombosis ").
- 1. PLT Function Assay (PFA 100): assess PLT function
 - Specificity > 90 % for severe PLT dysfunction of vWD (vWF plasma levels < 25%)</p>
 - Sensitivity > 24 41 % (low) in mild PLT secretion defect or Storage Pool Disease > (not screening tool).
- 2. PLT Aggregation Tests: (5 external aggregating factors; ADP, Collagen, Ristocetin, Arachidonic Acid, Adrenaline).
- 3. Von Willebrand Factor (Antigen & Activity).
- 4. Factor XIII assay (F XIII Deficiency >> normal PT & PTT).
 - **a.** Severe visceral bleeding (e.g. intracerebral hemorrhage) with normal labs? That's probably Factor 13 deficiency, it's an autosomal dominant inherited disorder.
 - b. Tx: Every 3wks factor XIII concentrate or FFP.
- 5. Human Plasminogen Activator Inhibitor (PAI-1).
- 6. Alpha 2 AntiPlasmin Inhibitor (α 2 AP).

Take home messages:

- Although screening tests are used widely to identify hemostatic abnormalities associated with bleeding,
- they are NOT perfect The Clinical suspicion for a bleeding disorder is Critical to determine extent of the laboratory investigations

Management in the Perioperative Stage:

Management of Bleeding PT:

- Therapeutic decisions should not be based solely on laboratory testing, since abnormalities in Plt function as measured by the tests mentioned are not necessarily predictive of the presence or absence of clinical bleeding.
- Since medications such as ASA are the most common causes of Plt dysfunction, a **careful history of medication use**, including use of over-the-counter aspirin-containing preparations, is crucial >> the most prudent decision prior to an operation or other invasive procedure may simply be to **withhold any medication in question prior to the procedure**.
- If a pt has a Hx of clinically significant bleeding suggestive of Plt dysfunction, whether provoked or spontaneous, appropriate Plt function tests should be obtained so that risk for bleeding can be adequately assessed and therapy chosen more rational.
- 1. **Desmopressin (dDAVP)** is commonly used to correct the hemostatic defect in VWD (releases endogenous VWF from the endothelium) effective in preventing bleeding after dental extraction and minor surgery in pts with milder Plt defects, including storage pool disease, acquired platelet dysfunction, cirrhosis or uremia, & cardiopulmonary bypass. significantly reduced mean operative and early postoperative blood loss. Plasma levels of vWF were higher after desmopressin than placebo.
- 2. **Platelet transfusion** may be required in pts with disordered Plt function indicated in cases of severe, uncontrolled bleeding, when prior treatments (eg, dDAVP, estrogen) have been unsuccessful, and/or in the presence of, or anticipation of, excessive traumatic or surgical bleeding.
- 3. Antifibrinolytic Agents (Tranexamic Acid, epsilon Aminocaproic Acid) may be helpful in reducing bleeding in pts with disordered plt function following dental extraction.
- 4. **Conjugated Estrogens** used most commonly for uremic bleeding or in pts with mild to moderate type 1 vWD. Intravenous estrogen 0.6 mg/kg per day for 4-5 days, oral estrogen 50 mg/kg per day, or transdermal estradiol 50 to 100 mcg/24 hours applied as a patch twice weekly have been shown to be effective, particularly for GI bleeding.
- 5. **Erythropoietin** used successfully in uremic pts to both reduce and prevent bleeding.
- 6. Recombinant Factor VIIa (rFVIIa) some success for Rx of bleeding in pts with congenital Plt disorders. Potential mechanisms >> a local procoagulant effect at sites of vascular damage or tissue factor-independent thrombin generation induced by binding of rFVIIa to the surface of activated Plts. Pts who cannot receive platelet transfusions because of alloimmunization or antibody formation to the absent platelet glycoprotein (eg, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome) may benefit from rFVIIa. one or more bolus infusions of approximately 90 to 100 mcg/kg. approved in Europe for use in pts with Glanzmann thrombasthenia refractory to Plt Tx. Benefits of rFVIIa must be balanced against the risk of thrombosis.

Extra info (from Doctor's slides)

Preoperative Management of Agents Affecting Hemostasis:

• Warfarin:

- Typically discontinue **5 days** before elective surgery (ie, last dose of warfarin is given on day minus 6).
- Check the PT/INR on the day before surgery & If INR is >1.5 >> ?? administer low dose oral vitamin K (1 2 mg) to hasten normalization of the PT/INR and recheck the following day.
- Proceed with surgery when the INR is ≤ 1.4 (An INR in the normal range is especially important in
 pts undergoing surgery with high bleeding risk (eg, intracranial, spinal, urologic) or if neuraxial
 anesthesia is to be used).
- Heparin / LMWH Bridging considered >> Pts with very high or high thromboembolic risk.

Heparin:

- Generally initiate heparin bridging 3 days before a planned procedure (2 days after stopping warfarin), when the PT/INR has started to drop below therapeutic range.

\rightarrow PRE OP:

- LMWH: Discontinue 24 hours before the planned surgery or procedure, based on a biologic half-life of most subcutaneous LMWH of ~ 3-5 hours. If a twice-daily LMWH regimen is given >> evening dose the night before surgery omitted. If a once-daily regimen is given (Dalteparin 200 IUs/kg), ½ of the total daily dose is given on the morning of the day before surgery >> ensures that no significant residual anticoagulant will be present at the time of surgery.
- UFH: Therapeutic dose IV infusion continue until 4-5 hours before the procedure, based on the biologic half-life of IV UFH of ~ 45 minutes. If SC UFH is used (dose of ~ 250 IUs/kg BID), the last dose can be given the evening before the procedure.

→ Post OP:

- Resumption of UFH & LMWH is similar, based on the onset of anticoagulation at ~ 1 hour after administration for both forms of heparin (peak anticoagulant activity at ~ 3-5 hours).
- The resumption of bridging, especially when given as a therapeutic-dose regimen >> <u>should be</u> <u>delayed until there is adequate hemostasis</u> based on a clinical assessment of the wound site, drainage fluid amount, and expected postoperative bleeding; coupled, where appropriate, with hemoglobin levels >> This assessment will vary depending on the surgery type and individual pt considerations, and it may be difficult for surgery where ongoing bleeding is not readily apparent (eg, cardiac, intracranial).
- **For Major Surgery** or those with a high bleeding risk procedure >> therapeutic-dose UFH or LMWH should be <u>delayed for 48 to 72 hours after hemostasis</u> has been secured.
- **For Minor Procedures** associated with a low bleeding risk in which bridging is used (eg, laparoscopic hernia repair) >> therapeutic-dose UFH or LMWH can usually be <u>resumed 24 hours</u> <u>after the procedure</u>.

:lass of	drug Clinical considerations	Recommended strategy for surgery with brief NPO state	Recommended strategy for surgery with prolonged NPO state	Anticoagulant	Renal function and dose	Interval between last dose and procedure NOTE: No anticoagulant is administered the day of the procedure		Resumption after procedure			
Aspirin	Continuation may cause	Discontinue aspirin	Resume with oral intake.			High bleeding risk	Low bleeding risk	High bleeding risk	Low bleeding risk		
	perioperative hemorrhage.	approximately 7 days prior to		Dabigatran	CrCl >50 mL/minute	Give last dose three days before	Give last dose two days before				
the ris	Discontinuation may increase the risk of vascular complications.	noncardiovascular surgery.					Dose 150 mg twice daily	procedure (ie, skip four doses on the two days before the procedure)	procedure (ie, skip two doses on the day before the procedure)		
	Discussion with cardiologist				CrCl 30 to 50 mL/minute	Give last dose five days before	Give last dose three days before		Resume 24 hours after surgery (ie, postoperative day 1)		
appro	appropriate for patients with cardiovascular indications.				Dose 150 mg twice daily	on the four days before the the t	procedure (ie, skip four doses on the two days before the procedure)				
P2Y12 receptor blockers	When used after cardiac	iac Ideally, elective procedures	Resume with oral intake.	Rivaroxaban	CrCl >50 mL/minute	Give last dose three days before procedure (ie, skip two doses on the two days before the procedure) Give last dose two days before procedure) Give last dose three days before procedure (ie, skip four doses on the two days before the procedure (ie, skip four doses on the two days before the procedure) Give last dose two days before procedure (ie, skip four doses on the two days before the procedure)		1			
(clopidogrel, prasugrel,	stenting procedure, if	should be delayed until the			Coll 20 to 50 ml (minute			Resume 48 to 72 hours after			
ticlopidine, ticagrelor)	discontinued can cause cardiac	inhibition with these agents is					the day before the procedure,				
	ischemia perioperatively. If				Dose 15 mg once daily						
	continued can result in bleeding complications. Should discuss	completed. When used for long- term stroke prophylaxis, should		Apixaban	CrCl >50 mL/minute						
	management with cardiologist.	be discontinued 7 to 10 days. If			Dose 5 mg twice daily						
	5	discontinuing, stop clopidogrel			CrCl 30 to 50 mL/minute						
		and ticagrelor at least 5 days, prasugrel 7 days, and ticlopidine 10 days before surgery. When restarting clopidogrel, consider using a loading dose.			Dose 2.5 mg twice daily						
				Edoxaban CrCl	CrCl 50 to 95 mL/minute	before the procedure (ie, skip b	Give the last dose two days before the procedure (ie, skip one dose on the day before the				
					Dose 60 mg once daily						
					CrCl 15 to 50 mL/min	before the procedure)	procedure)				

Perioperative management of oral direct thrombin inhibitors and factor Xa inhibitors:

Extra info (from Doctor's slides)

Coagulation Factor Levels Required For Hemostasis:

Factor	Plasma half-life	Hemostatic level*
Fibrinogen	2 to 4 days	50 to 100 mg/dL
Prothrombin (factor II)	3 to 4 days	20 to 30 percent
Factor V	36 hours	15 to 20 percent
Factor VII	4 to 6 hours	15 to 20 percent
Factor X	40 to 60 hours	15 to 20 percent
Factor XI	40 to 70 hours	15 to 20 percent
Factor XIII	11 to 14 days	2 to 5 percent
Factor V + factor VIII combined deficiency	36 hours for factor V and 10 to 14 hours for factor VIII $% \left({{\left[{{N_{\rm{B}}} \right]} \right]_{\rm{B}}} \right)$	15 to 20¶ percent
Multiple vitamin K-dependent factor deficiencies (factors II, VII, IX, X)	Refer to individual factor half-lives above	15 to 20¶ percent

A serine protease inhibitor (serpin) that degrades the serine proteases; (thrombin, IXa, Xa, XIa, XIIa). Constantly active, but its adhesion to these factors is increased by the administration of heparin. Quantitative or qualitative deficiency of antithrombin (in born or acquired) leads to Thrombophilia.

Inhibitors:

2. Protein C & Protein S

Antithrombin III

1.


 Activated to PCa by thrombin bound to thrombomodulin (protein on the surface of endothelial cells); then degrades (VIIIa & Va), reducing further thrombin generation. PS acts as cofactor of PC by enhancing binding of PCa to phospholipid surface; both contain gal residues.

3. Tissue Factor Pathway Inhibitor (TFPI)

- Inhibits VIIa-related activation of IX & X after its original initiation.

Hemostatic Phases:

Diagnostic Approach to Platelet Disorders:



Summary

Overview of Hemostasis						
Li	• The process through which bleeding is controlled.					
There are a set of the	 Primary Hemostasis: Endothelium Injury Platelet plug Von Willebrand Factor 			 Secondary Hemostasis: Clotting Factors Soluble Protein Fibrinogen converted to insoluble Fibrin. 		
		 atelet count (Normal: 150 - 00,000 (Thrombocytopenia) 50,000 - 100,000 (Mild): F < 50,000 (Severe): Needs Platelets are produced ir PLT Life Span (7 - 10 dates and the second second	follow up s intervention in the Bone Marrow b ays). ess of the	by fragmentation of the cytoplasm of megakaryocytes. Partial Thromboplastin time : Measures Effectiveness of the Intrinsic Pathway. NORMAL VALUE (25-40 SECS) 		
	Ble	eeding time : PROVIDES ASSESSMENT COUNT AND FUNCTION (2-8 MINUTES)		 Thrombin time : A Measure of Fibrinolytic Pathway. NORMAL VALUE 9-13 SECS. 		
Bleeding disorders						
Definition		•	• •		nability to form a proper blood clot. They y, trauma or menstruation.	
		Characterized by Mucocuta				
Disease		Etiology	Diag	nosis	Treatment	
			Quantitativ	e		
Immune Thrombocytopenic Purpura (ITP)		 Primary: Isolated thrombocytopenia due to immune platelet destruction (auto AB to megakaryocytes) Secondary. 	 Diagnosis of exclusion. CBC (isolated thrombocytopenia) PBS (large platelet) Antiplatelet antibodies (Anti-GpIIb/IIIa) 		No bleeding, count > 50,000: NO treatment - 1st line: • Steroids & IVIG - 2nd line: Splenectomy & Rituximab - Refractory: Romiplostim.	
			Qualitative			
Deficient platelet GPIb-IX		• Abnormal				
Glanzmann thrombasthenia		Autosomal recessive Deficient platelet GP IIb-IIIa	Normal platelets Abnormal results on platelet aggregation testing confirm the diagnosis.			
Secondary or Drug induced	£	Uremia (Renal disease) drugs: e.g. aspirin or clopidogrel	•		Treat underlying cause Stop the drug.	

Summary

Bleeding disorders cont.

Secondary hemostasis (only) disorders:

Characterized by hematomas, hemarthrosis, bruising, bleeding (mucosal, GI, GU, joint) deep bleeding.

Disease	Etiology	Diagnosis	Treatment
Hemophilia A	 Congenital: Inherited deficiency of factor VIII an X-linked recessive disorder Secondary: Development of autoantibodies most commonly directed against FVIII (ass. with pregnancy, malignancy, advanced age). 	 Factor VIII Assay: low. Mixing study (corrected) Normal VWF & PT. 	 Replacement of the deficient coagulation Factor
Hemophilia B	Inherited deficiency of factor IX; also called Christmas Disease; an X-linked recessive disorder.	 Factor IX Assay: low Mixing study (corrected) Normal VWF & PT. 	 Desmopressin Antifibrinolytic
Hemophilia C	Inherited deficiency of factor XI ; also called Rosenthal Syndrome; an autosomal recessive disorder (Ashkenazi Jews).	 Factor XI Assay: Low Normal PT & PTT 	agents (Tranexamic Acid, Aminocaproic Acid
Factor XIII Deficiency		 Factor XIII Assay: FXIII Deficiency Normal PT & PTT 	

Baseline factor activity level

- **Severe Hemophilia** : defined as <1 % factor activity (<0.01 IU/mL).
- ★ Moderate Hemophilia : defined as a factor activity level ≥1 % of normal and <5 % of normal (≥0.01 <0.05 IU/mL).
- ★ Mild Hemophilia : defined as a factor activity level ≥5 % of normal and <40 % of normal (≥0.05 <0.40 IU/mL).

Disorders not specific to one step of hemostasis.

Clinical features: Bleeding of Mucous membranes, skin cuts, post-trauma or postoperative

Disease	Etiology	Diagnosis	Treatment			
Von Willebrand Disease	(most common bleeding disorder) Defect of Von Willebrand Factor: Quantitative (type 1 & 3) Qualitative (type 2) Clinical features: Bleeding of Mucous membranes, skin cuts, post-trauma or postoperative					
	Congenital: Autosomal dominant. Normal function of VWF: - Mediate platelet adhesion. Acquired :rare, caused by autoantibodies	Normal aPTT in (Type 1 & 2). Prolonged aPTT in (Type 2N, 2B, & 3) vWF: Ag. FVIII assay (low in 2N & 3). Plt count (low in 2M).	 Replacement of exogenous vWF concentrate. Desmopressin Antifibrinolytic agents (Tranexamic Acid, Aminocaproic Acid 			
Disseminated Intravascular Coagulation	Trauma Septic shock Malignancy (esp <mark>APML)</mark> Major trauma	Prolonged PT and aPTT. decreased fibrinogen. Low plt. High LDH. Low haptoglobin.	- Treat underlying process . - <mark>fresh frozen plasma (FFP)</mark> - Cryoprecipitate			

Summary

How to differentiate between bleeding disorders?								
Disorder	Platelets	Bleeding time	INR	РТ	aPTT	Other:		
Thrombocytopenia	↓	1	Normal	Normal	Normal	-		
Platelet dysfunction (e.g. aspirin therapy or uremia)	Normal	ſ	Normal	Normal	Normal	-		
Extrinsic pathway (e.g. Factor VII def.)	Normal	Normal	ſ	ſ	Normal	Specific factor assay: Low Mixing study: correctable		
Intrinsic pathway (e.g. Hemophilia A, B & heparin therapy).	Normal	Normal	Normal	Normal	ſ	-		
Von Willebrand disease (vWD)	Normal	Ť	Normal	Normal	Normal/↑	vWF assay: low (dominant) FVIII assay (low)		
Disseminated intravascular coagulation (DIC)	Ļ	ſ	ſ	Ť	Ť	-		

Lecture Quiz

Q1:A 38-year-old woman presents with a 3-day history of fever and confusion. She was previously healthy and is taking no medications. She has not had diarrhea or rectal bleeding. She has a temperature of 38°C (100.4°F) and a blood pressure of 145/85. Splenomegaly is absent. She has no petechiae but does have evidence of early digital gangrene of the right second finger. Except for confusion the neurological examination is normal. Her laboratory studies reveal the following: Hemoglobin: 8.7 g/dL, Platelet count: 25,000/µL ,Peripheral smear: numerous fragmented RBCs, few platelets, LDH 562 IU/L(normal < 180), Creatinine: 2.7 mg/dL, Liver enzymes: normal, Prothrombin time/PTT/fibrinogen levels: normal. What is the most likely pathogenesis of her condition?

- A- Disseminated intravascular coagulation
- **B-Antiplatelet antibodies**
- C- Failure to cleave von Willebrand factor multimers
- D- Verotoxin-induced endothelial damage

Q2:A 25-year-old woman complains of persistent bleeding for 5 days after a dental extraction. She has noticed easy bruisability since childhood, and was given a blood transfusion at age 17 because of prolonged bleeding after an apparently minor cut. She denies ecchymoses or bleeding into joints. Her father has noticed similar symptoms but has not sought medical care. Physical examination is normal except for mild oozing from the dental site. She does not have splenomegaly or enlarged lymph nodes. Her CBC is normal, with a platelet count of 230,000. Her prothrombin time is normal, but the partial thromboplastin time is mildly prolonged. The bleeding time is 12 minutes (normal 3-9 minutes). What is most appropriate way to control her bleeding?

- A- Factor VIII concentrate
- B- Fresh frozen plasma
- C- Desmopressin (DDAVP)
- D- Whole blood transfusion e. Single donor platelets

Q3: A patient with bacterial endocarditis develops thrombophlebitis while hospitalized. His course in the hospital is uncomplicated. On discharge he is treated with penicillin, rifampin, and warfarin. Therapeutic prothrombin levels are obtained on 15 mg/d of warfarin. After 2 weeks, the penicillin and rifampin are discontinued. Which of the following is the best next step in management of this patient?

- A- Cautiously increase warfarin dosage.
- B- Continue warfarin at 15 mg/d for about 6 months.
- C- Reduce warfarin dosage.
- D- Stop warfarin therapy.

Q4:A 70-year-old intensive care unit patient complains of fever and shaking chills. The patient develops hypotension, and blood cultures are positive for gram-negative bacilli. The patient begins bleeding from venipuncture sites and around his Foley catheter. Laboratory studies are as follows: Hct: 38% WBC: 15,000/µL Platelet count: 40,000/µL (normal 150,000-400,000) Peripheral blood smear: fragmented RBCs PT: elevated PTT: elevated Plasma fibrinogen: 70 mg/dL (normal 200-400). Which of the following is the best course of therapy in this patient?

A-Begin heparin.

- B- Treat underlying disease.
- C-Begin plasmapheresis.
- D-Begin red blood cell transfusion





Females co-leaders:

Raghad AlKhashan Amirah Aldakhilallah Males co-leaders: Mashal AbaAlkhail Nawaf Albhijan

Send us your feedback: We are all ears!

